328 related articles for article (PubMed ID: 17560452)
1. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
Coppola G; Novo S
Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
[TBL] [Abstract][Full Text] [Related]
2. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
4. Statins and peripheral arterial disease.
Markel A
Int Angiol; 2015 Oct; 34(5):416-27. PubMed ID: 25410295
[TBL] [Abstract][Full Text] [Related]
5. Does the preventive effect of different drugs depend on location of the atherosclerotic process?
Poredos P; Jezovnik MK
Int Angiol; 2008 Aug; 27(4):274-80. PubMed ID: 18677288
[TBL] [Abstract][Full Text] [Related]
6. Peripheral artery disease: therapeutic advances.
Shamoun F; Sural N; Abela G
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):539-53. PubMed ID: 18402543
[TBL] [Abstract][Full Text] [Related]
7. Peripheral arterial disease: a review of disease awareness and management.
Watson K; Watson BD; Pater KS
Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
[TBL] [Abstract][Full Text] [Related]
8. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
Bárczi G; Merkely B
Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
[TBL] [Abstract][Full Text] [Related]
9. The role of biomarkers and genetics in peripheral arterial disease.
McDermott MM; Lloyd-Jones DM
J Am Coll Cardiol; 2009 Sep; 54(14):1228-37. PubMed ID: 19778662
[TBL] [Abstract][Full Text] [Related]
10. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease.
van Gestel YR; Hoeks SE; Sin DD; Simsek C; Welten GM; Schouten O; Stam H; Mertens FW; van Domburg RT; Poldermans D
Am J Cardiol; 2008 Jul; 102(2):192-6. PubMed ID: 18602520
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk factor management is poorer in diabetic patients with undiagnosed peripheral arterial disease than in those with known coronary heart disease or cerebrovascular disease. Results of a nationwide study in tertiary diabetes centres.
González-Clemente JM; Piniés JA; Calle-Pascual A; Saavedra A; Sánchez C; Bellido D; Martín-Folgueras T; Moraga I; Recasens A; Girbés J; Sánchez-Zamorano MA; Mauricio D;
Diabet Med; 2008 Apr; 25(4):427-34. PubMed ID: 18341592
[TBL] [Abstract][Full Text] [Related]
12. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
Chi YW; Jaff MR
Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study.
Nylaende M; Kroese AJ; Morken B; Stranden E; Sandbaek G; Lindahl AK; Arnesen H; Seljeflot I
Vasc Med; 2007 Nov; 12(4):275-83. PubMed ID: 18048463
[TBL] [Abstract][Full Text] [Related]
14. [The best of vascular medicine in 2006].
Mounier-Vehier C; Stephan D; Aboyans V; Beregi JP; Lacroix P; Léger P; Long A; Sevestre MA;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():47-55. PubMed ID: 17405565
[TBL] [Abstract][Full Text] [Related]
15. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
[TBL] [Abstract][Full Text] [Related]
16. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected.
Paraskevas KI; Giannoukas AD; Mikhailidis DP
Ann Vasc Surg; 2009; 23(5):690-9. PubMed ID: 19747617
[TBL] [Abstract][Full Text] [Related]
17. An emerging paradigm in atherosclerosis: focus on subclinical disease.
Miller M
Postgrad Med; 2009 Mar; 121(2):49-59. PubMed ID: 19332962
[TBL] [Abstract][Full Text] [Related]
18. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
; Leizorovicz A; Becker F
Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
[TBL] [Abstract][Full Text] [Related]
19. Statins and stroke prevention.
Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy before and after revascularization: anticoagulation, antiplatelet agents, and statins.
Dagher NN; Modrall JG
Semin Vasc Surg; 2007 Mar; 20(1):10-4. PubMed ID: 17386359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
